Canada's Med BioGene Files for US IPO; Plans to Launch RT qPCR-based Lung Cancer Test This Year | GenomeWeb

Med BioGene, a diagnostic developer based in Vancouver, BC, filed in late December for an initial public offering in the US.

In a registration statement filed with the US Securities and Exchange Commission, Med BioGene said that it will use the proceeds from the IPO to complete the validation of its first test, called LungExpress Dx, on a real-time, quantitative reverse transcriptase PCR platform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.